Medtide Inc. (HKG:3880)

Market Cap	3.31B
Revenue (ttm)	634.40M +28.9%
Net Income	241.89M +267.3%
EPS	1.81 +332.1%
Shares Out	141.80M
PE Ratio	12.89
Forward PE	11.14
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,200
Open	23.40
Previous Close	23.36
Day's Range	23.36 - 23.82
52-Week Range	19.00 - 41.72
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Medtide

Medtide Inc., a contract research, development, and manufacturing company, provides early-stage discovery, pre-clinical research, clinical development, and commercial-stage production services. It offers peptide new chemical entity discovery synthesis, manufacturing, and control development and commercial manufacturing services. The company focuses on developing oral and/or injectable glucagon, such as peptide-1 (GLP-1) molecule products. Its research and development technology platforms include OmniPeptSynth, PeptiConjuX, PeptiNuclide LinkTech...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Employees: 566
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3880

Financial Performance

In 2025, Medtide's revenue was 570.09 million, an increase of 28.91% compared to the previous year's 442.23 million. Earnings were 217.37 million, an increase of 267.35%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 10, 2026

Data Sources Report a data error